1. Artificial intelligence automates and augments baseline impedance measurements from pH-impedance studies in gastroesophageal reflux disease
- Author
-
Benjamin D. Rogers, Daniel Sifrim, Sabine Roman, Amit Patel, Sabyasachi Samanta, Kevan Ghobadi, Edoardo Savarino, and C. Prakash Gyawali
- Subjects
Adult ,Male ,Artificial intelligence ,Esophageal pH Monitoring ,Treatment outcome ,Convenience sample ,Gastroesophageal reflux disease ,Asymptomatic ,Proof of Concept Study ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Electric Impedance ,Humans ,Baseline impedance ,pH-impedance monitoring ,Prospective Studies ,Aged ,business.industry ,Gastroenterology ,Reflux ,Proton Pump Inhibitors ,Middle Aged ,medicine.disease ,Mean nocturnal baseline impedance ,Treatment Outcome ,ROC Curve ,Symptom improvement ,030220 oncology & carcinogenesis ,Case-Control Studies ,GERD ,Clinical value ,Gastroesophageal Reflux ,Linear Models ,Feasibility Studies ,030211 gastroenterology & hepatology ,Female ,medicine.symptom ,business - Abstract
Artificial intelligence (AI) has potential to streamline interpretation of pH-impedance studies. In this exploratory observational cohort study, we determined feasibility of automated AI extraction of baseline impedance (AIBI) and evaluated clinical value of novel AI metrics.pH-impedance data from a convenience sample of symptomatic patients studied off (n = 117, 53.1 ± 1.2 years, 66% F) and on (n = 93, 53.8 ± 1.3 years, 74% F) anti-secretory therapy and from asymptomatic volunteers (n = 115, 29.3 ± 0.8 years, 47% F) were uploaded into dedicated prototypical AI software designed to automatically extract AIBI. Acid exposure time (AET) and manually extracted mean nocturnal baseline impedance (MNBI) were compared to corresponding total, upright, and recumbent AIBI and upright:recumbent AIBI ratio. AI metrics were compared to AET and MNBI in predicting ≥ 50% symptom improvement in GERD patients.Recumbent, but not upright AIBI, correlated with MNBI. Upright:recumbent AIBI ratio was higher when AET 6% (median 1.18, IQR 1.0-1.5), compared to 4% (0.95, IQR 0.84-1.1), 4-6% (0.89, IQR 0.72-0.98), and controls (0.93, IQR 0.80-1.09, p ≤ 0.04). While MNBI, total AIBI, and the AIBI ratio off PPI were significantly different between those with and without symptom improvement (p 0.05 for each comparison), only AIBI ratio segregated management responders from other cohorts. On ROC analysis, off therapy AIBI ratio outperformed AET in predicting GERD symptom improvement when AET was 6% (AUC 0.766 vs. 0.606) and 4-6% (AUC 0.563 vs. 0.516) and outperformed MNBI overall (AUC 0.661 vs. 0.313).BI calculation can be automated using AI. Novel AI metrics show potential in predicting GERD treatment outcome.
- Published
- 2021